Cell line · CVCL_1594
NCI-H838
Cancer cell line, Homo sapiens. Lung adenocarcinoma. 34 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. NCI-H838. Cell lines, record CVCL_1594. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1594
On this page
Cell line
As Cellosaurus gives it.
- Name
- NCI-H838
- Accession
- CVCL_1594
- RRID
- RRID:CVCL_1594
- Synonyms
- H838, H-838, NCIH838
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 59Y
- Category
- Cancer cell line
- Diseases
- Lung adenocarcinoma (NCIt C3512)
- Derived from
- Lymph node (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers34
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Circulating Tumour Cell GALNT13 Expression Is Associated with Prognosis and Treatment Response in Non-Small Cell Lung Cancer. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer. | Biomolecules | 2026 | Its Methods give the RRID and name the line | PubMed | |
| E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. | Elife | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| De novo sphingolipid biosynthesis necessitates detoxification in cancer cells. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress. | Elife | 2022 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 34
See all 34 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | NCI-H838 EGFR (L858R/+) | CVCL_LD05 | Cell lines | |
| Derived from it | NCI-H838 EGFR (delE746-A750/+) | CVCL_LE02 | Cell lines | |
| Derived from it | NCI-H838 KRAS (G12D/+9n) | CVCL_A4IK | Cell lines | |
| Derived from it | NCI-H838 KRAS (G12V/+9n) | CVCL_A4IL | Cell lines |
Cell banks4
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-5844 | ATCC | |
| CLS | 305097 | CLS | |
| KCB | KCB 2021016YJ | Cellosaurus | |
| NCI-DCTD | NCI-H838 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1594
GET https://conductscience.org/api/cell-lines/v1/CVCL_1594/papers?page=2